CTL102/CB1954 gene therapy: Began Phase I/II testing

ML Laboratories plc (LSE:MLB), Liverpool, U.K. Product: CTL102/CB1954 gene therapy Business: Cancer Therapeutic category: Gene therapy, Cytotoxic Target: CB1954 monofunctional alkylating agent Descrip...